Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Condition(s)
Leukemia Lymphoma

Age Group
0-9 years 10-17 years 18-26 years

Phase(s)
1

Genetic Double Helix Genetic
JCAR017, JCARH125
Trial Summary & Details
Ages: Child, Adult, Older Adult
Condition: Non Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

(Trial terminated: Eligible subjects will be enrolled in Celgene’s long-term follow-up protocol for subjects previously treated with a CAR T-cell product.)

This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.

Status
Other
Location(s)
City of Hope, Duarte, CA
Massachusetts General Hospital, Boston, MA

Sponsor/Collaborators:
Juno Therapeutics, Inc.
Contact
Not available.